Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T03:28:01.392Z Has data issue: false hasContentIssue false
  • English
  • Français

Aspects of metabolic changes in first-episode drug-naïve schizophrenic patients

Published online by Cambridge University Press:  26 February 2013

Marat G. Uzbekov ,
Eduard Misionzhnik ,
Isaak Gurovich ,
Alexander Shmukler  and
Tatjana Moskvitina
Marat G. Uzbekov*
Affiliation:
Department of Brain Pathology, Research Institute of Psychiatry, Moscow, Russia
Eduard Misionzhnik
Affiliation:
Department of Brain Pathology, Research Institute of Psychiatry, Moscow, Russia
Isaak Gurovich
Affiliation:
First Psychotic Episode Clinic, Research Institute of Psychiatry, Moscow, Russia
Alexander Shmukler
Affiliation:
First Psychotic Episode Clinic, Research Institute of Psychiatry, Moscow, Russia
Tatjana Moskvitina
Affiliation:
Department of Brain Pathology, Research Institute of Psychiatry, Moscow, Russia
*
Marat G. Uzbekov, Department of Brain Pathology, Research Institute of Psychiatry, Poteshnaya 3, 107076 Moscow, Russia. Tel: +7 495 963 14 09; Fax: +7 495 963 10 53; E-mail: uzbekovmg@mtu-net.ru
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim

The aim of the study was to investigate the state of parameters characterising different sites of metabolism and the degree of endogenous intoxication in first-episode drug-naïve schizophrenic [first episode of schizophrenia (FES)] patients. It is hypothesised that the FES is the initial step in the development of pathologically disturbed biochemical status that is characteristic of chronic schizophrenia.

Methods

Platelet monoamine oxidase (MAO) and serum semicarbazide-sensitive amine oxidase (SSAO) activities, serum concentrations of middle-mass endotoxic molecules (MMEM) and malondialdehyde and parameters of the serum albumin functional state were measured in 26 FES patients and 15 age-matched healthy controls.

Results

Severity of disorder before the treatment was 75.5 ± 2.2, according to Positive and Negative Syndrome Scale score. FES patients were characterised by significant increase in MAO activity (99%) and MMEM concentration (124%) and significant decrease in SSAO activity (26%) as compared with controls. Changes of all other parameters were insignificant. Regression analysis has showed a significant relationship of three parameters – MAO, SSAO and MMEM, with values of PANNS score. Two methods of extraction of factor analysis revealed that MAO and SSAO belonged to Factor 1, whereas MMEM and albumin functional parameters belonged to Factor 2.

Conclusion

Comparing our earlier data on chronic schizophrenic patients with present data, we hypothesise that FES patients are at the stage that leads to a stable, pathological state of metabolism.

Keywords

amine oxidaseendogenous intoxicationfirst-episode drug naïvemonoamine oxidaseschizophrenia
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 25 , Issue 5 , October 2013 , pp. 268 - 274
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Cunningham Owens, DG, Miller, P, Lawrie, SM, Johnstone, EC. Pathogenesis of schizophrenia: a psychopathological perspective. Br J Psychiatry 2005;186:386–393.CrossRefGoogle Scholar
2.Buckley, PF, Evans, D. First episode schizophrenia – an opportunity for therapeutic intervention. J Postgrad Med 2006;51:5–19.Google Scholar
3.Ohlsen, RI, O'Toole, MS, Purvis, RGet al. Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 2004;14(Suppl. 4):S445–S451.CrossRefGoogle ScholarPubMed
4.Stöber, G, Ben-Shachar, D, Cardon, Met al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP Task Force on biological markers. World J Biol Psychiatry 2009;10:127–155.CrossRefGoogle ScholarPubMed
5.Huang, JT, Leweke, FM, Oxley, Det al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006;3:2145–2157.CrossRefGoogle ScholarPubMed
6.Jindal, RD, Keshavan, MS. Neurobiology of the early course of schizophrenia. Expert Rev Neurother 2008;8:1093–1100.CrossRefGoogle ScholarPubMed
7.Laruelle, M, Abi-Dargham, A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999;13:358–371.CrossRefGoogle ScholarPubMed
8.Ohrmann, P, Siegmund, A, Suslow, Tet al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naïve and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res 2007;41:625–634.CrossRefGoogle ScholarPubMed
9.Uzbekov, MG, Misionzhnik, EY. Nonspecific syndrome of endogenous intoxication as an integral component of pathogenesis of mental disorders. Russian J Psychiatry 2000;4:56–65.Google Scholar
10.Uzbekov, MG, Misionzhnik, EY, Maximova, NM, Vertogradova, OP. Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action. Hum Psychopharmacol Clin Exp 2006;21:109–115.CrossRefGoogle ScholarPubMed
11.World Health Organization (WHO). The tenth revision of the international classification of diseases and related health problems. Geneva: World Health Organization (WHO), 1992.Google Scholar
12.Uzbekov, MG. Complex approach for the evaluation of neurochemical homeostasis in patients with mental disorders. In: Krasnov VN, editor. Interaction of fundamental science and practice in modern psychiatry. Moscow: MEDPRACTICA-M, 2007. p. 349–350.Google Scholar
13.McEwen, CM, Cohen, JD. An amine oxidase in normal human serum. J Lab Clin Med 1963;62:766–776.Google ScholarPubMed
14.Voloshina, ON, Moskvitina, TA. Method of estimation of platelet monoamine oxidase activity. Lab Delo 1985;5:289–291.Google Scholar
15.Balakleevski, AI. Colorimetric method of estimation of serum monoamine oxidase activity. Lab Delo 1976;3:151–153.Google Scholar
16.Mihara, M, Uchiyama, M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978;86:271–278.Google ScholarPubMed
17.Korobeinikova, EN. A modified technique for measuring lipid peroxidation products in the thiobarbituric acid test. Lab Delo 1989;7:8–10.Google Scholar
18.Babb, AL, Farrell, PC, Uvelli, DA, Scribner, BH. Hemodialyzer evaluation by examination of solute molecular weight spectra. Trans Am Soc Artif Intern Organs 1972;18:98–105.CrossRefGoogle Scholar
19.Nikolaichik, VV, Moin, VM, Kirkovski, VVet al. The method of estimation of middle molecules. Lab Delo 1991;10:13–18.Google Scholar
20.Gryzunov, YA, Miller, YI, Dobretsov, GE, Pestova, AB. Fluorescent method of determining mass concentration of human serum albumin. Klin Lab Diagn 1994;5:27–31.Google Scholar
21.Moin, VM, Misionzhnik, EIu, Kuznetsova, ZI, Gryzunov, IuA, Kirkovskiĭ, VV, Uzbekov, MG, Zubovskiĭ, DK. Characteristics of the method and reagents in fluorescent determination of effective and total concentration of serum albumin. Klin Lab Diagn 1994;5:33–35.Google Scholar
22.Gyzunov, YA, Syreytschikova, TI, Komarova, MNet al. Serum albumin binding sites properties in donors and schizophrenia patients: the study of fluorescent decay of the probe K-35 using synchrotron pulse excitation. Nucl Instrum Methods 2000;448:478–482.CrossRefGoogle Scholar
23.Stahl, SM. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacol Bull 1985;21:663–671.Google Scholar
24.Chen, K, Wu, HF, Shih, JC. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem 1993;61:187–190.CrossRefGoogle ScholarPubMed
25.Spivak, B, Kosower, N, Zipzer, Yet al. Platelet monoamine oxidase activity in neuroleptic-naïve schizophrenic patients: lack of influence of chronic perphenazine treatment. Neuropharmacology 1994;17:83–88.CrossRefGoogle ScholarPubMed
26.Coron, B, Campiob, B, Thibaut, Fet al. Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. Psychiatry Res 1996;62:221–226.CrossRefGoogle ScholarPubMed
27.Ertugrul, A, Ucar, G, Basar, K, Demir, B, Yabanoglu, S, Ulug, B. Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin level. Psychiatry Res 2007;149:49–57.CrossRefGoogle Scholar
28.Mosolov, SN, Uzbekov, MG, Saikin, MA, Misionzhnik, EY, Tsukarzi, EE, Molodetskikh, AV. On the use of intravenous low-intensity helium and neon laser therapy and alteration of biochemical parameters in schizophrenic patients resistant to pharmacotherapy. Social Clin Psychiatry 1999;9:57–62.Google Scholar
29.Uzbekov, MG, Misionzhnik, EY, Neduva, AA, Malin, DI. Changes in the level of middle molecules and some other biochemical parameters in patients with endogenous psychosis under plasmapheresis. Social Clin Psychiatry 1997;7:93–99.Google Scholar
30.Prilipko, LL, Erin, AN, Beliaev, BS, Piatnitskii, AN, Siuniakov, SA. Activation of lipid peroxidation in the bodies of schizophrenic and manic-depressive patients. Zh Nevropatol Psikhiatr Im S S Korsakova 1987;87:100–103.Google ScholarPubMed
31.Beckman, KB, Ames, BN. The free radical theory of aging matures. Physiol Rev 1998;78:547–581.CrossRefGoogle ScholarPubMed
32.Gorkin, VZ. Studies on the nature and specific inhibition of monoamine oxidases. In: Keleman K, Magyar K, Visi ES, editors. Neuropharmacology '85. Budapest: Akademiai Kiado, 1985. p. 9–14.Google Scholar
33.Boomsma, F, Bhaggoe, UM, van der Houwen, AMB, van der Meiracker, AH. Plasma semicarbazide-sensitive amine oxidase in human(patho)physiology. Biochim Biophys Acta 2003;1647:48–54.CrossRefGoogle ScholarPubMed
34.Gong, B, Boor, PJ. The role of amine oxidases in xenobiotic metabolism. Expert Opin Drug Metab Toxicol 2006;2:559–571.CrossRefGoogle ScholarPubMed
35.Strolin Benedetti, M, Whomsley, R, Baltes, E. Involvement of enzymes other then CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2006;2:895–921.CrossRefGoogle ScholarPubMed
36.Baron, M, Asnis, L, Gruen, R, Levitt, M. Plasma amine oxidase and genetic vulnerability to schizophrenia. Arch Gen Psychiatry 1983;40:275–279.CrossRefGoogle ScholarPubMed
37.Callingham, BA, Crosbie, AE, Rous, BA. Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Prog Brain Res 1995;106:305–321.CrossRefGoogle ScholarPubMed
38.Umanskii, MA, Pinchuk, LB, Pinchuk, VG. Syndrome of endogenous intoxication. Kiev: Naukova Dumka, 1991.Google Scholar
39.Turianitsa, IM, Mishanich, II, Rostoka, LM. Middle molecule spectrum of the blood serum in patients with a continuously progressive paranoid form of schizophrenia undergoing treatment. Zh Nevropatol Psikhiatr Im S S Korsakova 1988;88:109–111.Google ScholarPubMed
40.Chalenko, VV. Possible causes of the increase of concentration of molecules of middle mass in pathologic states. Pathol Physiol Exp Ther 1991;4:13–14.Google Scholar
41.Kovalevskii, AN, Nifantieva, OE. About the screening method of the estimating of middle mass molecules. Lab Delo 1989;10:13–18.Google Scholar
42.Ringoir, S, Vanholder, R, Massry, SG, eds. Uremic toxins. New York, London: Plenum Press, 1987.CrossRefGoogle Scholar
43.Kragh-Hansen, U, Chuang, VTG, Otagiri, M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002;225:695–704.CrossRefGoogle Scholar
44.Gryzunov, YA, Smolina, NV, Uzbekov, MGet al. Conformational changes of serum albumin in mental disorders. In: Kovalev V, Tuzikov A, Ablameyko S, Aleinikova O, editors. Advanced information and telemedicine technologies for health. Minsk: Belarus United Institute of Informatics Problems, 2008. p. 158–163.Google Scholar
45.Uzbekov, MG, Misionzhnik, EY, Shmukler, ABet al. Biochemical disturbances accompanying first episode of schizophrenia. In: Kovalev V, Tuzikov A, Ablameyko S, Aleinikova O, editors. Advanced information and telemedicine technologies for Health. Minsk: Belarus United Institute of Informatics Problems, 2008. p. 297–301.Google Scholar